Do you want to read an article? Please log in or register.
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial
Genitourinary Cancer
Related content
Genitourinary Cancer
Darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC) by disease volume: Subgroup analysis of the phase 3 ARANOTE trial
J Clin Oncol
Saad F, Shore ND, Vjaters E, Olmos D, Littleton N, Liu A, Testa I, Mo M, Srinivasan S, Parambath Haresh K
doi: 10.1200/JCO.2025.43.5_suppl.15
Genitourinary Cancer
Age-related efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) and docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subgroup analysis of ARASENS
J Clin Oncol
Carles J, Tombal BF, Hussain MHA , Saad F, Fizazi K, Montesa Pino A, Méndez-Vidal MJ, Rodriguez-Vida A, Castellano D, Borrega P, Adorjan P, Moretones C, Dissanayake M, Smith MR
doi: 10.1200/JCO.2025.43.5_suppl.143
Genitourinary Cancer
Concomitant G-CSF use in maintaining an efficacious dose and safe delivery of docetaxel in combination with darolutamide in patients with metastatic hormone sensitive prostate cancer (mHSPC): ARASENS, a phase 3 study
J Clin Oncol
Ong M, Suzuki H, Smith MR, Tombal BF, Hussain MHA, Saad F, Fizazi K, Verholen F, Pham H, Srinivasan S, Lalani AKA
doi: 10.1200/JCO.2025.43.5_suppl.152
Genitourinary Cancer
Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review
BJU Int
Raval AD, Chen S, Littleton N, Constantinovici N, Goebell PJ
doi: 10.1111/bju.16577
COMMENTED
Genitourinary CancerNuclear Medicine
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
★ 3
Recommended and commented by
Prof. Dr Ken Herrmann, Faculty Member
Lancet
Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, Crosby M, Piulats JM, Fléchon A, Wei XX, Mahammedi H, Roubaud G, Študentová H, Nagarajah J, Mellado B, Montesa-Pino Á, Kpamegan E, Ghebremariam S, Kreisl TN, Wilke C, Lehnhoff K, Sartor O, Fizazi K, PSMAfore Investigators
doi: 10.1016/S0140-6736(24)01653-2
Genitourinary Cancer
Association of Deep and Durable Prostate-specific Antigen Responses with Outcomes in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials
Eur Urol Oncol
Wallis CJD, Ekberg S, Morgans AK, Boegemann M, Paracha N, Gallagher E, Crowther MJ, Shore N
doi: 10.1016/j.euo.2025.03.001
COMMENTED
Genitourinary CancerNuclear Medicine
Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study
★ 3
Recommended and commented by
Prof. Dr Ken Herrmann, Faculty Member
Lancet Oncol
Azad AA, Bressel M, Tan H, Voskoboynik M, Suder A, Weickhardt AJ, Guminski A, Francis RJ, Saghebi J, Dhiantravan N, Joshua AM, Emmett L, Horvath L, Murphy DG, Hsiao E, Balakrishnar B, Lin P, Redfern A, Macdonald W, Ng S, Lee ST, Pattison DA, Nadebaum D, Kirkwood ID, Hofman MS, UpFrontPSMA Study Team
doi: 10.1016/S1470-2045(24)00440-6
Genitourinary Cancer
Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review
JAMA Oncol
Hussain M, Fizazi K, Shore ND, Heidegger I, Smith MR, Tombal B, Saad F
doi: 10.1001/jamaoncol.2024.0591
Genitourinary Cancer
Screening for Predictive Factors of Efficacy of Second-Generation Androgen Receptor Axis-Targeted Agents in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Prostate
Ueda T, Hayakawa K, Horiguchi G, Murashita J, Shiraishi T, Fujimoto S, Miyashita M, Saito Y, Gabata Y, Sako S, Takahashi H, Fujihara A, Minami T, Yamamoto Y, Okumi M, Hongo F, Okihara K, Fujita K, Ukimura O
doi: 10.1002/pros.24855